A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers
NCT03500627
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
8
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy
Interventions
DRUG:
OP-101
Sponsor
Orpheris, Inc.